JP2018530592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530592A5 JP2018530592A5 JP2018519437A JP2018519437A JP2018530592A5 JP 2018530592 A5 JP2018530592 A5 JP 2018530592A5 JP 2018519437 A JP2018519437 A JP 2018519437A JP 2018519437 A JP2018519437 A JP 2018519437A JP 2018530592 A5 JP2018530592 A5 JP 2018530592A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sglt
- patient
- myopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010068836 Metabolic myopathy Diseases 0.000 claims 4
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 3
- 208000007345 glycogen storage disease Diseases 0.000 claims 3
- 229920002527 Glycogen Polymers 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 1
- 229960003345 empagliflozin Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 208000025973 glycogen metabolism disease Diseases 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242030P | 2015-10-15 | 2015-10-15 | |
| US62/242,030 | 2015-10-15 | ||
| US201662347747P | 2016-06-09 | 2016-06-09 | |
| US62/347,747 | 2016-06-09 | ||
| PCT/EP2016/074601 WO2017064193A1 (en) | 2015-10-15 | 2016-10-13 | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530592A JP2018530592A (ja) | 2018-10-18 |
| JP2018530592A5 true JP2018530592A5 (enExample) | 2019-11-21 |
Family
ID=57130398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519437A Pending JP2018530592A (ja) | 2015-10-15 | 2016-10-13 | 代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US20170106009A1 (enExample) |
| EP (1) | EP3362055B1 (enExample) |
| JP (1) | JP2018530592A (enExample) |
| WO (1) | WO2017064193A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| DK2396005T3 (da) | 2009-02-13 | 2026-02-09 | Boehringer Ingelheim Int | Sglt2 hæmmer til at forbedre glykæmisk kontrol |
| PT2486029E (pt) | 2009-09-30 | 2015-10-14 | Boehringer Ingelheim Int | Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP4678242A3 (en) | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| EP3362055B1 (en) | 2015-10-15 | 2023-01-18 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy |
| KR20190084096A (ko) | 2016-11-10 | 2019-07-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| CN111110949B (zh) * | 2018-11-01 | 2021-07-09 | 上海市第六人民医院 | 胰岛素注射量确定方法及装置、计算机存储介质及设备 |
| CN115515435A (zh) * | 2020-02-11 | 2022-12-23 | 沃尔夫森医疗中心 | 有效治疗溃疡性结肠炎的方法 |
| EP4341401A1 (en) * | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| JP4147111B2 (ja) | 2001-02-27 | 2008-09-10 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体およびその医薬用途 |
| CN103030617A (zh) * | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| DE602005009745D1 (de) | 2004-12-16 | 2008-10-23 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| WO2007025943A2 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| AU2006289093A1 (en) | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| AR059489A1 (es) | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| WO2008049923A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| CA2668623A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| AU2007316613B2 (en) | 2006-11-09 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
| CN101638423B (zh) | 2008-07-29 | 2012-09-05 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 根皮苷衍生物及其制备方法和用途 |
| WO2010049678A2 (en) * | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
| US20110014284A1 (en) | 2009-02-13 | 2011-01-20 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| AU2014200258B2 (en) | 2009-02-13 | 2016-05-12 | Boehringer Ingelheim International Gmbh | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia |
| DK2396005T3 (da) | 2009-02-13 | 2026-02-09 | Boehringer Ingelheim Int | Sglt2 hæmmer til at forbedre glykæmisk kontrol |
| EA020798B1 (ru) | 2009-09-30 | 2015-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2015150299A2 (en) * | 2014-04-01 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
| WO2016046150A1 (en) | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| EP3362055B1 (en) | 2015-10-15 | 2023-01-18 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitor for use in the treatment of a metabolic myopathy |
-
2016
- 2016-10-13 EP EP16781135.5A patent/EP3362055B1/en not_active Revoked
- 2016-10-13 WO PCT/EP2016/074601 patent/WO2017064193A1/en not_active Ceased
- 2016-10-13 JP JP2018519437A patent/JP2018530592A/ja active Pending
- 2016-10-13 US US15/292,234 patent/US20170106009A1/en not_active Abandoned
-
2019
- 2019-03-14 US US16/353,000 patent/US20190209596A1/en not_active Abandoned
-
2020
- 2020-04-09 US US16/844,091 patent/US20200397809A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/809,618 patent/US20220323473A1/en not_active Abandoned
-
2023
- 2023-11-10 US US18/506,167 patent/US20240082283A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530592A5 (enExample) | ||
| Karolczak et al. | Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study | |
| JP2015523321A5 (enExample) | ||
| JP2017513836A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| JP2010248252A5 (enExample) | ||
| WO2016105118A3 (ko) | Gpr120 효능제로서의 바이아릴 유도체 | |
| AR103371A1 (es) | Composiciones y métodos para diagnosis y tratamiento de síndrome metabólico, uso | |
| JP2009537554A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| CN110546150A (zh) | 含吡唑基的三并环类衍生物、其制备方法和应用 | |
| JP2017014206A5 (enExample) | ||
| WO2015038552A3 (en) | Aspirin formulation for increased efficacy | |
| BR112015004012A2 (pt) | combinações de inibidores de sglt 2 e fármacos anti-hipertensivos | |
| JP2014210824A5 (enExample) | ||
| JP2005527551A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2018503685A5 (enExample) | ||
| JP2007238598A5 (enExample) | ||
| JP2021534105A5 (enExample) | ||
| JP2016538288A5 (enExample) | ||
| JP2014533256A5 (enExample) | ||
| JP2012506429A5 (enExample) | ||
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions |